Today, March 19th, 2026, FSHD Europe announced its collaboration with TREAT-NMD and the PaLaDIn consortium to develop an FSHD disease model for health technology assessment (HTA), FSHD patient journey and patient advocacy toolkits.
FSHD Europe strengthens its capacity in HTA evidence generation through a partnership with the institute for Medical Technology Assessment (iMTA | Erasmus University), a globally recognised leader in HTA research and part of Erasmus University Rotterdam, the Netherlands.
“We are honoured to collaborate with TREAT-NMD and PaLaDIn partners like the FSHD Society,” commented Ria de Haas, CEO of FSHD Europe. “Working together reinforces our shared goal to enhance the quality of life for patients and their families, while accelerating access to treatments for FSHD.”
You can read the full press release here.